Rebeccah A McKibben1, Sabina A Haberlen2, Wendy S Post3, Todd T Brown1, Matthew Budoff4, Mallory D Witt4, Lawrence A Kingsley5, Frank J Palella6, Chloe L Thio1, Eric C Seaberg2. 1. Department of Medicine, Johns Hopkins School of Medicine. 2. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 3. Department of Medicine, Johns Hopkins School of Medicine Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 4. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California. 5. Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pennsylvania. 6. Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: Hepatitis C virus (HCV) infection may increase the risk of cardiovascular disease (CVD). We evaluated the association of chronic HCV infection and coronary atherosclerosis among participants in the Multicenter AIDS Cohort Study. METHODS: We assessed 994 men with or without human immunodeficiency virus (HIV) infection (87 of whom had chronic HCV infection) for coronary plaque, using noncontrast coronary computed tomography (CT); 755 also underwent CT angiography. We then evaluated the associations of chronic HCV infection and HIV infection with measures of plaque prevalence, extent, and stenosis. RESULTS: After adjustment for demographic characteristics, HIV serostatus, behaviors, and CVD risk factors, chronic HCV infection was significantly associated with a higher prevalence of coronary artery calcium (prevalence ratio, 1.29; 95% confidence interval [CI], 1.02-1.63), any plaque (prevalence ratio, 1.26; 95% CI, 1.09-1.45), and noncalcified plaque (prevalence ratio, 1.42; 95% CI, 1.16-1.75). Chronic HCV infection and HIV infection were independently associated with the prevalence of any plaque and of noncalcified plaque, but there was no evidence of a synergistic effect due to HIV/HCV coinfection. The prevalences of coronary artery calcium, any plaque, noncalcified plaque, a mixture of noncalcified and calcified plaque, and calcified plaque were significantly higher among men with an HCV RNA load of ≥2 × 10(6) IU/mL, compared with findings among men without chronic HCV infection. CONCLUSIONS: Chronic HCV infection is associated with subclinical CVD, suggesting that vigilant assessments of cardiovascular risk are warranted for HCV-infected individuals. Future research should determine whether HCV infection duration or HCV treatment influence coronary plaque development.
BACKGROUND:Hepatitis C virus (HCV) infection may increase the risk of cardiovascular disease (CVD). We evaluated the association of chronic HCV infection and coronary atherosclerosis among participants in the Multicenter AIDS Cohort Study. METHODS: We assessed 994 men with or without human immunodeficiency virus (HIV) infection (87 of whom had chronic HCV infection) for coronary plaque, using noncontrast coronary computed tomography (CT); 755 also underwent CT angiography. We then evaluated the associations of chronic HCV infection and HIV infection with measures of plaque prevalence, extent, and stenosis. RESULTS: After adjustment for demographic characteristics, HIV serostatus, behaviors, and CVD risk factors, chronic HCV infection was significantly associated with a higher prevalence of coronary arterycalcium (prevalence ratio, 1.29; 95% confidence interval [CI], 1.02-1.63), any plaque (prevalence ratio, 1.26; 95% CI, 1.09-1.45), and noncalcified plaque (prevalence ratio, 1.42; 95% CI, 1.16-1.75). Chronic HCV infection and HIV infection were independently associated with the prevalence of any plaque and of noncalcified plaque, but there was no evidence of a synergistic effect due to HIV/HCV coinfection. The prevalences of coronary arterycalcium, any plaque, noncalcified plaque, a mixture of noncalcified and calcified plaque, and calcified plaque were significantly higher among men with an HCV RNA load of ≥2 × 10(6) IU/mL, compared with findings among men without chronic HCV infection. CONCLUSIONS:Chronic HCV infection is associated with subclinical CVD, suggesting that vigilant assessments of cardiovascular risk are warranted for HCV-infected individuals. Future research should determine whether HCV infection duration or HCV treatment influence coronary plaque development.
Authors: W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe Journal: Circulation Date: 1975-04 Impact factor: 29.690
Authors: Anthony J Silvestre; John B Hylton; Lisette M Johnson; Carmoncelia Houston; Mallory Witt; Lisa Jacobson; David Ostrow Journal: Am J Public Health Date: 2006-05-02 Impact factor: 9.308
Authors: Matthew S Freiberg; Debbie M Cheng; Kevin L Kraemer; Richard Saitz; Lewis H Kuller; Jeffrey H Samet Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Naser Ahmadi; Vahid Nabavi; Fereshteh Hajsadeghi; Ferdinand Flores; William J French; Song S Mao; David Shavelle; Ramin Ebrahimi; Matthew Budoff Journal: Am J Cardiol Date: 2011-01 Impact factor: 2.778
Authors: Paolo Maggi; Giuseppe Bruno; Francesco Perilli; Annalisa Saracino; Anna Volpe; Carmen Santoro; Nicoletta Ladisa; Gioacchino Angarano Journal: In Vivo Date: 2017-01-02 Impact factor: 2.155
Authors: Alison L Bailey; Saif Al-Adwan; Eliea Sneij; Nicholas Campbell; Matthew E Wiisanen Journal: Curr Cardiol Rep Date: 2021-04-06 Impact factor: 2.931
Authors: Gregory M Lucas; Mohamed G Atta; Derek M Fine; Allison M McFall; Michelle M Estrella; Katie Zook; James H Stein Journal: Arterioscler Thromb Vasc Biol Date: 2016-09-08 Impact factor: 8.311
Authors: Carmine Rossi; Janet Raboud; Sharon Walmsley; Curtis Cooper; Tony Antoniou; Ann N Burchell; Mark Hull; Jason Chia; Robert S Hogg; Erica E M Moodie; Marina B Klein Journal: BMC Infect Dis Date: 2017-04-04 Impact factor: 3.090
Authors: Jonathan Shuter; Alain H Litwin; Mark S Sulkowski; Addi Feinstein; Avram Bursky-Tammam; Stephen Maslak; Andrea H Weinberger; Hannah Esan; Kate S Segal; Brianna Norton Journal: Nicotine Tob Res Date: 2017-07-01 Impact factor: 4.244